Press Room

Webinar - Thermodynamics applied to amorphous solid dispersion development

Start
Tuesday, February 18, 2020 - 15:00
End
Tuesday, February 18, 2020 - 16:00
Location: online

 

Tuesday, February 18, 2020
3:00 pm GMT   |   10:00 am EST (NA)   |   7:00 am PST (NA)

Registrations to the webinar are subject to approval

 

Speakers

Luis Sousa, PhD - Analytical Chemist

 

Watch On-Demand Webinar

 

Amorphous solid dispersions (ASDs) have been used extensively in the pharmaceutical industry for improving the solubility of poorly water-soluble drugs. Despite their advantages in terms of solubility, amorphous dispersions are not physically stable and tend to phase separate/crystallize with time, thus losing the initial solubility advantage. For that reason, it is essential to investigate the miscibility and the solubility limit of drugs in the polymeric matrixes. Determination of these limits allows defining a safe range of drug loads that can be manufactured and minimize potential stability issues that are inherent to supersaturated ASDs. In this webinar, we will present the most common methods used to determine drug solubility in polymeric matrices, including Hovione’s own thermodynamic approach to solubility determination.

In addition, we will also give an overview of the methodologies used to assess and predict long-term stability of amorphous materials and discuss the thermodynamic and kinetic contributions to drug crystallization in the solid state. In this section we will focus on the evaluation of the kinetics of relaxation and molecular mobility of amorphous materials, as a function of temperature. These are important aspects to be considered in a preliminary evaluation of stability, not only for pure amorphous drugs but also for supersaturated amorphous solid dispersions.

 

Key Learning Objectives:

  • Identify advantages and disadvantages of the different methods used to determine drug-polymer solubility
  • Understand the complexity of phenomena involved in physical stability of amorphous drugs
  • Establish correlations between kinetic and thermodynamic parameters and stability

 

 

Watch On-Demand Webinar

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025